Amsterdam’s Avidicure exits stealth mode with €43.8M to develop new antibody therapies
Based out of Amsterdam, Avidicure, a biotechnology company, announced its launch with $50M (approximately €43.8M) in a seed financing round led by EQT Life Sciences.